PubMed Health⌕ Search

Biomedical subjects

F Loré

Publications and source records attributed to F Loré.

At least 19 recordsLinked to original sources

Multiple endocrine neoplasia type 2 syndromes may be associated with renal malformations.

OBJECTIVE: The RET proto-oncogene is known to be the susceptibility gene for various disease phenotypes, including multiple endocrine neoplasia type 2 (MEN 2). Recent studies have also suggested an involvement of RET in the development of the mammalian kidney. Although kidney agenesis or dysgenesis has been observed in mice lacking functional ret, no clinically relevant kidney abnormalities have been reported in individuals with known RET mutations and familial medullary thyroid carcinoma (FMTC). We have studied a family with five members affected with isolated FMTC. DNA analysis was performed and the involved RET mutation was identified. Amongst these patients were a woman and her son. DESIGN: Case report. SETTING: University department. PATIENTS: A 32-year-old woman and her son with FMTC and unilateral renal agenesis. RESULTS: The woman's abdominal ultrasound findings demonstrated unilateral renal absence of the left kidney. Her son, when only a few months old, had undergone surgical treatment for Hirschsprung's disease. Abdominal ultrasonography was performed recently, and left-side renal absence was diagnosed. Intravenous pyelography confirmed the agenesis of his left kidney, whilst the contralateral kidney displayed compensatory hypertrophy. CONCLUSIONS: The involvement of the RET proto-oncogene in the early growth and differentiation of the human kidney is now generally accepted. We believe that at least a proportion of patients with MEN 2 may have undiagnosed renal malformations. We suggest therefore that noninvasive imaging techniques, such as ultrasonography, should be used to explore the presence of renal abnormalities in subjects with demonstrated RET mutations.

Adult↗

Cerebrotendinous xanthomatosis: pathophysiological study on bone metabolism.

A condition of osteopenia in some cerebrotendinous xanthomatosis (CTX) patients led us to investigate bone metabolism in 8 patients belonging to 5 families. Serum calcium, phosphate and vitamin D metabolites were in the normal range; a reduction in total body density and impairment of intestinal radiocalcium absorption were found in the majority of our patients.

Absorptiometry, Photon↗

Pathophysiological aspects of calcium metabolism in spasmophilia.

In order to clarify the pathophysiological mechanisms of spasmophilia, 34 subjects (31 females and 3 males) with spasmophilia were studied. The diagnosis of spasmophilia was based on a specific clinical protocol and electromyographic criteria. In the study, markedly reduced plasma ionized calcium and serum magnesium concentrations were observed together with slightly and non-significantly reduced plasma calcium and phosphate levels. An impairment of intestinal radiocalcium absorption was also noticed. Parathyroid secretion did not show any significant disturbance, but circulating calcitonin levels were found to be significantly lower than in normal subjects. The mean value of serum 25OHD was within the normal range, while a slight reduction in bone Gla protein, an index of osteoblastic activity, was detected. No difference between patients with spasmophilia and normal subjects was observed concerning 47Ca kinetics in red blood cells. The studies indicated that an impaired intestinal calcium transport together with low levels of circulating calcitonin represent the most important pathophysiological determinants of spasmophilia.

Adult↗

Effect of a long-term treatment with 1,25-dihydroxyvitamin D3 on osteocalcin in postmenopausal osteoporosis.

Serum bone Gla-protein (BGP or osteocalcin) was measured in 25 women with histologically confirmed postmenopausal osteoporosis before and during long-term treatment with 1 microgram/day of 1,25-dihydroxyvitamin D3(1,25(OH)2D3). Basal serum BGP was significantly lower in osteoporotic women (3.8 +/- 1.4 ng/ml) than in age-matched controls (6.8 +/- 2.0 ng/ml). During 1,25(OH)2D3 therapy serum BGP increased so that the mean of the values observed on treatment (4.8 +/- 1.5) was significantly higher than the mean basal value. It is known that BGP synthesis is stimulated by 1,25(OH)2D3 and that serum BGP is a specific marker of bone formation; therefore, it is possible that the low basal levels of osteocalcin we observed were related to the low serum 1,25(OH)2D concentrations reported in osteoporotic women and that the increase in BGP levels observed under 1,25(OH)2D3 treatment was a consequence of osteoblast stimulation.

Aged↗

Studies on the hydroxylation of vitamin D in man.

The authors have studied some of the factors influencing vitamin D hydroxylases in man, using two indirect experimental approaches. In the first study they have considered the effect of a long-term treatment with 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) on the serum levels of 25-hydroxyvitamin D (25-OHD) in postmenopausal osteoporosis, a condition in which high serum levels of 25-OHD and low mean levels of 1,25(OH)2D have been observed. In the second study the effects of the infusion of physiological doses of human parathyroid hormone (PTH) on the serum levels of 1,25(OH)2D and 24,25(OH)2D have been investigated. In the first study a decrease in the circulating levels of 25-OHD was observed during 1,25(OH)2D3 treatment. This could be considered as an indirect evidence of an inhibitory action of 1,25(OH)2D3 on 25-hydroxylase: in this view 1,25(OH)2D3 treatment decreases 25-hydroxylase activity, which is higher than normal in postmenopausal osteoporosis due to the low levels of 1,25(OH)2D. In the second study PTH infusion was followed by a remarkable increase in 1,25(OH)2D serum levels as a result of 1 alpha-hydroxylase stimulation, which was much higher in patients with hypoparathyroidism. The determination of 24,25(OH)2D levels during PTH infusion indicated an inhibitory effect on 24-hydroxylase.

Aged↗

Vitamin D status in the extreme age of life.

The aim of the present study was to investigate vitamin D status in the extreme age of life and to assess the ability of elderly people to synthesize vitamin D in skin, in response to artificial ultraviolet irradiation, and to hydroxylate the newly synthesized vitamin in the liver. The authors have determined the serum 25-hydroxyvitamin D concentrations in 43 healthy subjects (17 males and 26 females) aged 84 years or more. The changes induced in 25-OHD serum levels by whole-body artificial ultraviolet irradiation have also been studied in 10 healthy volunteers aged 41-90 years and, as a control, in 8 normal subjects aged 24-40 years. Serum 25-OHD has been determined, after lipid extraction of samples and column chromatography, by competitive protein binding assay using rat serum as the source of binding protein. The mean 25-OHD serum level in the group studied was 5.7 +/- 4.3 ng/ml, much lower than the mean observed in normal subjects aged 20-40 years (21.3 +/- 8.2 ng/ml). Men had higher levels than women. In the age group 84-89 years 25-OHD levels were higher than in subjects aged 90-96. Serum 25-OHD increased remarkably in all our normal subjects in response to artificial ultraviolet irradiation. Age-related differences in 25-OHD response to irradiation were not significant. The results of the present study indicate that vitamin D deficiency is common in the extreme age of life. It is probably a consequence of poor diet and lack of exposure to sunshine rather than of an impairment of cutaneous synthesis or liver hydroxylation of vitamin D.

Age Factors↗

The hormonal form of vitamin D in the pathophysiology and therapy of postmenopausal osteoporosis.

Sixty-two women with symptomatic postmenopausal osteoporosis underwent long-term treatment with 1,25-dihydroxyvitamin D3. The following results were obtained: i) a dramatic improvement of the intestinal transport of radioactive calcium, which was impaired prior to the treatment; ii) non significant increases in fasting serum calcium; iii) significant increases in the 24 h urinary excretion of calcium and phosphate, resulting from the improvement of intestinal calcium absorption, and a decrease in the urinary cAMP/Cr ratio; iv) non significant changes in serum phosphate, serum alkaline phosphatase, urinary hydroxyproline; v) non significant increases in bone mineral content; vi) relief from pain and improvement of motility in all the patients; vii) no side effect was noticed. In conclusion the treatment with 1,25-dihydroxyvitamin D3 was shown to be useful in postmenopausal osteoporosis.

Aged↗

Calcitonin levels in normal subjects according to age and sex.

To evaluate the effect of age and sex on plasma calcitonin in human beings, the concentrations of the hormone were measured in 63 normal subjects aged 13-87 years of both sexes. In another study 30 healthy women were studied, 14 of them were pre-menopausal, 16 were post-menopausal. Plasma calcitonin was determined by means of a radioimmunoassay, using delayed tracer addition for increasing sensitivity. The antibody was produced in rabbits against pure synthetic human calcitonin and was specific for the aminoacid sequence 17 to 32 in the calcitonin molecule. A second antibody was used as a precipitating agent. A mean plasma calcitonin level of 71.3 +/- 37.0 SD pg/ml was observed. Women were found to have lower levels than men, the mean values being 63.4 +/- 34.7 pg/ml and 92.6 +/- 35.4 pg/ml respectively. The difference was statistically significant (P less than 0.005). No significant correlation was found between calcitonin levels and age of subjects. Premenopausal women, however, showed higher levels of plasma calcitonin than post-menopausal women, the mean values being 88.5 +/- 38.4 pg/ml and 54.0 +/- 33.6 pg/ml, respectively. This difference was also significant (P less than 0.01). Possible implications of these data are discussed.

Adolescent↗

[A rapid method for assay of 25-hydroxyvitamin D in serum].

A simplified assay for 25-hydroxyvitamin D is reported. In this procedure ethanol extraction is used in order to obtain a better protein precipitation and a higher recovery of added tritiated 25-hydroxyvitamin D3. Extraction is followed by column chromatography on Sep-pak Silica cartridges. The eluate is dried and directly used for competitive protein binding assay. The method shows two main advantages: it is less time consuming and is easier to perform than existing procedures.

25-Hydroxyvitamin D 2↗

[Assay of 24,25-dihydroxyvitamin D by competitive protein binding].

A competitive protein binding radioassay for 24,25-dihydroxyvitamin D in human serum has been developed, which is relatively simple and rapid. Acetonitrile is used for sample extraction and protein precipitation. column chromatography is then performed in a Sep-pak cartridge. High pressure liquid chromatography follows. The dried eluate is assayed using rat serum as the source of binding protein. Since 25-hydroxyvitamin D3 and 24,25-dihydroxyvitamin D3 are equipotent in their competitive displacement of tritiated 25-hydroxyvitamin D3 from at serum, 25-hydroxyvitamin D3 can be used as the assay standard.

24,25-Dihydroxyvitamin D 3↗

Adrenal function and essential hypertension.

A study of the adrenal function in patients with essential hypertension was performed using gas-liquid chromatography to separate and measure the daily urinary excretion of individual 17-ketosteroids, pregnanediol and pregnanetriol in basal conditions and after a dexamethasone suppression test. The purpose of the study was to detect alterations of adrenal function possibly indicative of some role of the adrenal cortex in the pathogenesis of hypertension. The results showed normal urinary levels of 17-ketosteroids, pregnanediol and pregnanetriol in most patients. Higher values were observed in the remaining cases. Dexamethasone suppression tests confirmed that steroid excess in these patients was of adrenal origin.

17-Ketosteroids↗